Table 3.
Univariate and multivariate analyses for progression-free survival and overall survival
| Characteristics | All patients (n = 133), n (%) | Progression-free survival |
Overall survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
| Age (years) | |||||||||
| <70 | 83 (62) | 1 | 0.06 | 1 | 0.12 | 1 | 0.21 | — | — |
| ≥70 | 50 (38) | 0.67 (0.44-1.02) | 0.71 (0.47-1.09) | 0.73 (0.45-1.19) | — | ||||
| ECOG-PS | |||||||||
| 0 | 54 (40) | 1 | 0.03 | 1 | 0.02 | 1 | <0.001 | 1 | 0.002 |
| 1-2 | 79 (60) | 1.54 (1.04-2.29) | 1.63 (1.09-2.45) | 2.37 (1.45-3.85) | 2.40 (1.40-4.11) | ||||
| Location of primary tumor | |||||||||
| Right colon | 92 (69) | 1 | 0.49 | — | - | 1 | 0.04 | 1 | 0.37 |
| Left colon or rectum | 41 (31) | 0.86 (0.57-1.31) | — | 0.62 (0.39-0.98) | 0.80 (0.49-1.30) | ||||
| Number of metastatic sites | |||||||||
| Less than three organs | 80 (60) | 1 | 0.05 | 1 | 0.63 | 1 | 0.02 | 1 | >0.99 |
| Three or more organs | 53 (40) | 1.47 (1.00-2.17) | 1.11 (0.72-1.72) | 1.74 (1.11-2.73) | 1.00 (0.60-1.68) | ||||
| Liver metastases | |||||||||
| No | 57 (43) | 1 | 0.05 | 1 | 0.21 | 1 | 0.03 | 1 | 0.30 |
| Yes | 76 (57) | 1.51 (1.01-2.25) | 1.32 (0.86-2.00) | 1.67 (1.05-2.66) | 1.33 (0.78-2.27) | ||||
| Peritoneal metastases | |||||||||
| No | 60 (45) | 1 | 0.02 | 1 | 0.04 | 1 | 0.05 | 1 | 0.01 |
| Yes | 73 (55) | 1.57 (1.06-2.32) | 1.59 (1.03-2.46) | 1.57 (1.00-2.47) | 1.98 (1.19-3.30) | ||||
| Primary tumor resected | |||||||||
| Yes | 104 (78) | 1 | 0.20 | — | — | 1 | 0.07 | 1 | 0.28 |
| No | 29 (22) | 1.35 (0.85-2.15) | — | 1.64 (0.98-2.75) | 1.38 (0.78-2.46) | ||||
| Prior lines of therapy | |||||||||
| 0-1 | 89 (67) | 1 | 0.31 | — | — | 1 | 0.03 | 1 | 0.01 |
| ≥2 | 44 (33) | 1.23 (0.82-1.84) | — | 1.63 (1.05-2.56) | 1.83 (1.13-2.96) | ||||
| MSI status | |||||||||
| MSS | 111 (83) | 1 | 0.85 | — | 1 | 0.04 | 1 | 0.08 | |
| MSI high | 20 (15) | 0.95 (0.57-1.61) | — | 0.48 (0.24-0.96) | 0.50 (0.23-1.08) | ||||
| Time to metastasis | |||||||||
| Metachronous | 45 (34) | 1 | 0.13 | — | — | 1 | 0.35 | — | — |
| Synchronous | 88 (66) | 1.37 (0.91-2.06) | — | 1.25 (0.78-2.03) | — | ||||
Bold/italic are statistically significant P values.
Bini, binimetinib; Cetux, cetuximab; CI, confidence interval; ECOG-PS, Eastern Cooperative Group Performance Status; Enco, encorafenib; HR, hazard ratio; MSI, microsatellite instability; MSS, microsatellite stable; N, number.